Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial

被引：0

作者：

Ahn, M. -J. ^{[1
]}

Delmonte, A. ^{[2
]}

Ghosh, S. ^{[3
]}

Hochmair, M. ^{[4
,5
]}

Yang, T. -Y. ^{[6
]}

Yang, J. C. -H. ^{[7
,8
]}

Han, J. -Y. ^{[9
]}

Hansen, K. Holmskov ^{[10
]}

Wu, Y. ^{[11
]}

Wan, Y. ^{[11
]}

Lin, H. M. ^{[11
]}

Kretz, J. ^{[12
]}

Hupf, B. ^{[11
]}

Kurec, A. M. ^{[13
]}

Churchill, E. N. ^{[14
]}

Fram, R. J. ^{[11
]}

Cabasag, C. J. ^{[15
]}

Goriya, V. ^{[16
]}

Zhao, Y. ^{[17
]}

Gemmen, E. ^{[18
]}

Campelo, M. R. Garcia ^{[19
,20
]}

机构：

[1] Sungkyunkwan Univ, Dept Med Oncol, Samsung Med Ctr, Div Hematol,Sch Med, Seoul, South Korea

[2] IRCCS Ist Romagnolo Studio Tumori Dino Amadori I, Cesena, Italy

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria

[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria

[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan

[7] Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[9] Natl Canc Ctr, Goyang, South Korea

[10] Odense Univ Hosp, Odense, Denmark

[11] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[12] Takeda Pharmaceut Int AG, Glattpark Opfikon Zurich, Zurich, Switzerland

[13] Takeda Pharmaceut Int Singapore Emerging Markets, Singapore, Singapore

[14] Takeda Pharmaceut USA Inc, Lexington, MA USA

[15] IQVIA RDS France, Courbevoie, France

[16] IQVIA RDS France, Courbevoie, France

[17] IQVIA RDS Shanghai Co Ltd, Shanghai, Peoples R China

[18] IQVIA Falls Church, Falls Church, VA USA

[19] Univ Hosp Coruna, Dept Med Oncol, La Coruna, Spain

[20] Biomed Res Inst INIBIC A Coruna, La Coruna, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Brigatinib; ALK plus NSCLC; ALK TKI;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.12B.03

引用

页码：S200 / S200

页数：1

共 50 条

[31] Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK plus advanced NSCLC with or without baseline CNS metastases (mets)
Krebs, M. G.
Lin, J. J.
Pal, N.
Polito, L.
Trinh, H. T. L.
Hilton, M. M. S. M.
Smoljanovic, V.
Kurtsikidze, N.
Archer, V.
Zhang, Q.
ANNALS OF ONCOLOGY, 2021, 32 : S959 - S959
[32] Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C-H.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Ni, Q.
Zhang, P.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2020, 31 : S840 - S841
[33] Nivolumab plus chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)
Park, Keunchil
Yang, James Chih-Hsin
Girard, Nicolas
Mok, Tony
Gainor, Justin
Nakagawa, Kazuhiko
Wu, Yi-Long
Xu, Wanning
Yang, Rong
Ohe, Yuichiro
ANNALS OF ONCOLOGY, 2019, 30
[34] Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James C. H.
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Garcia Campelo, Maria Rosario
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Gupta, Neeraj
Hanley, Michael J.
Ni, Quanhong
Zhang, Pingkuan
Popat, Sanjay
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3592 - +
[35] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Chang, Gee-Chen
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Huang, Yen-Hsiang
Su, Kang-Yi
Yu, Sung-Liang
Tseng, Jeng-Sen
SCIENTIFIC REPORTS, 2020, 10 (01)
[36] Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C-H.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A. I.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2018, 29 : 746 - 746
[37] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Gee-Chen Chang
Tsung-Ying Yang
Kun-Chieh Chen
Kuo-Hsuan Hsu
Yen-Hsiang Huang
Kang-Yi Su
Sung-Liang Yu
Jeng-Sen Tseng
Scientific Reports, 10
[38] Brigatinib in Japanese patients (pts) with ALK plus NSCLC: Final results from the phase 2 J-ALTA trial.
Zhang, Pingkuan
Kumagai, Toru
Yoshida, Tatsuya
Nishio, Makoto
Toyozawa, Ryo
Seto, Takashi
Nakagawa, Kazuhiko
Ohe, Yuichiro
Yamamoto, Nobuyuki
Kudou, Kentarou
Asato, Takayuki
Goto, Koichi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Brigatinib in crizotinib-refractory ALK1 NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
Hochmair, M. J.
Tiseo, M.
Reckamp, K. L.
West, H. L.
Groen, H. J.
Langer, C. J.
Reichmann, W.
Kerstein, D.
Kim, D-W.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2017, 28
[40] A real-world multicenter analysis of first (1L) and second line (2L) treatment of advanced pancreatic adenocarcinoma (APC).
Yu, Irene S.
Spratlin, Jennifer L.
Tang, Patricia A.
Lee-Ying, Richard M.
Goodwin, Rachel Anne
Meyers, Brandon Matthew
Ramjeesingh, Ravi
Armstrong, Dawn Elizabeth
Vickers, Michael M.
Zhang, Hanbo
Kim, Christina
Cheung, Winson Y.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →